US Patent Issued to XENOTHERA on Feb. 3 for "Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer" (French Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,184, issued on Feb. 3, was assigned to XENOTHERA (Nantes, France).

"Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer" was invented by Odile Duvaux (Nantes, France) and Bernard Vanhove (Nantes, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an association of non-human mammal polyclonal antibodies directed against cancer cells; and at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies for its use for preventing and/or treating a cancer in a mammal patient. The association as such is also considered."...